Treatment
Infliximab clinical trials
We’re tracking 37 recruiting studies that include Infliximab, each written for real people, not researchers, below.
Recruiting studies
- NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT05313620RecruitingPhase 4
Tofacitinib effect on clotting tests in ulcerative colitis
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
Madrid, MadridAges 18 years+ - NCT05823532RecruitingPhase 4
Anti-inflammatory treatment test in people with schizophrenia
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
Atlanta, GeorgiaAges 18–55 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06941376RecruitingPhase 2
Medication study for relapsing polychondritis
This trial tests if a type of medication that adjusts the immune system can help control symptoms of relapsing polychondritis. It is for people with mild to moderate active disease that needs more treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06995170Recruiting
Polyamines and IBD progression study
This study looks at how certain natural chemicals called polyamines relate to the activity of inflammatory bowel disease (IBD). It aims to understand if these chemicals can help predict disease progression.
Xi'an, ShaanxiAges 18–65 - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT01706692Recruiting
Study registry for targeted treatments in psoriasis patients
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
AarauAges 18 years+ - NCT07470502Recruiting
Study of infliximab for children and teens with IBD
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
Florence, ItalyAges 3–18 - NCT07491913Recruiting
Stopping biologic therapy for Takayasu arteritis in stable patients
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
IstanbulAges 18 years+ - NCT04646187Enrolling by invitationPhase 4
Lowering biologic doses for Crohn’s and ulcerative colitis
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
GhentAges 12–25
Common questions
- Are there clinical trials studying Infliximab?
- Yes. Clin2 currently lists 37 recruiting studies that include Infliximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Infliximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Infliximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Infliximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.